Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

CRI Lifetree Conducting Pain Addiction Study

By R&D Editors | September 11, 2012

The extent to which genetics contribute to the development of addiction to opioid pain medication is the subject of a new investigation, funded by the National Institutes of Health (NIH). CRI Lifetree, a leader in specialized early stage research with particular expertise in pain, human abuse liability, psychiatry, neurology and diabetes, is among the facilities awarded the NIH research grant.

The grant will enable researchers to conduct the first-ever, genome-wide association study of the characteristics of patients who develop addiction after being treated with opioids for chronic noncancerous pain. The project is expected to form the basis of follow-up studies with far-reaching impact on public health and clinical treatment decisions. In awarding the grant, the review committee noted the lack of similar studies in the field and lauded the potential for increasing important knowledge.

More than 100 million people in America live with chronic pain, according to the Institute of Medicine. Prescription opioids are increasingly used to treat chronic noncancerous pain but have been accompanied by a rising burden of opioid abuse and addiction. The dearth of studies means little information is available to reliably inform physicians as to which patients may develop problems. Estimates of drug abuse range from 3 to 40 percent of opioid-treated patients.

“The country has two serious problems—opioid addiction and chronic pain,” said Lynn R. Webster, MD, Medical Director of CRI Lifetree and study co-investigator. “There are no good ways to identify who is vulnerable to abuse. This study, over the course of the next several years, should address this question.”

Charles O’Brien, MD, PhD, of the University of Pennsylvania, will head the research team, which also includes investigators from the University of Washington and encompasses expertise in addiction psychiatry, pain management and psychiatric genetics. The study is expected to follow 4,000 patients with chronic noncancerous pain, half of whom have been treated for opioid addiction and half of whom have been maintained on opioid therapy for greater than six months without demonstrating signs of addiction.

A particular focus of the genetic analysis will be the mu opioid receptor (MOR) gene (OPRM1), which prior research suggests is critical to the drugs’ rewarding properties.  The investigative team will also compare differences among groups with varying psychiatric illnesses, drug-seeking behaviors, substance use and socioeconomic factors.  It is hoped that if specific behavioral and genetic factors that predispose a person to addiction can be isolated, that knowledge can be used to test patients for vulnerability prior to beginning opioid therapy.

Date: September 6, 2012
Source: CRI Lifetree

Related Articles Read More >

For the first time, scientists grow beating human-pig hearts for 21 days
Open-source Boltz-2 can speed binding-affinity predictions 1,000-fold
Thermo Fisher’s new Orbitrap Excedion Pro targets complex biotherapeutics for drug development
FDA’s new ‘Elsa’ AI set to expedite clinical protocol reviews
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE